Yves Poumay, researcher on skin pathologies
As the largest and heaviest organ in the human body, the skin is the focus of Professor Yves Poumay's research. For nearly 30 years, within the Cells and Tissues laboratory (LabCeTi), he has been developing in vitro epidermal models that reproduce skin pathologies to better understand and treat them. A pioneering approach that offers alternatives to animal experimentation! On the eve of an international congress devoted to dermatology research organised at UNamur (see below), he talks about the importance of melanoma screening and details the latest advances in dermatology made in his laboratory.
See content
QUALIblood, a spin-off for the medicine of tomorrow
One of the major concerns with the disease caused by Covid-19 is its severe course, which causes many problems that can lead to hospital overload. Early detection of whether or not a person is at risk of developing a severe form of the disease is therefore crucial to optimise patient care and hospital resource management. This is one of the objectives of the study carried out by QUALIblood, a UNamur spin-off, in collaboration with the Department of Pharmacy and many other industrial and hospital partners. Exploration of a cutting-edge technology at the service of health.
See content
An AstraZeneca-FNRS-FWO Foundation award for Charlotte Beaudart
On 13 December 2023, Charlotte Beaudart, a new academic at the University of Namur Faculty of Medicine, will be awarded a prize at the annual ceremony for Belgian scientific research in support of her innovative research on the subject of ageing.
See content
Public thesis defense - Pauline TRICQUET
The Elongator complex is involved in the addition of 5'-carboxylmethyluridine (cm5U)-derived modifications to transfer RNAs (tRNAs), thereby influencing the translation of certain messenger RNAs (mRNAs) and helping to maintain the integrity of the proteome. This complex is involved in a variety of biological processes, and is of particular importance in oncology. The identification of chemical inhibitors of Elongator is of significant interest in both basic and pharmaceutical research.Through a yeast screen, this work reveals a potential new role for Elongator and identifies a chemical inhibitor of the complex. This compound presents itself as an interesting candidate as a pharmacological inhibitor, opening up new perspectives for the search for anti-cancer therapies.
See content
A new teaching unit at UNamur: "One Health
In an ever-changing world, where health, environmental and societal crises are intertwined, it is becoming imperative to rethink health in a global and interconnected approach. It was against this backdrop that the Faculty of Medicine at the University of Namur inaugurated its new "One Health" teaching unit (UE) on Thursday February 06, 2025, in the presence of Minister Yves Coppieters. This initiative, offered to all UNamur undergraduates, aims to train tomorrow's healthcare professionals in a systemic vision, where human, animal and environmental health are considered as one and the same reality.
See content
Charlotte Beaudart, Namuroise of the Year: reward for her research on ageing
Helping us to age independently and in good health. This is the aim of Charlotte Beaudart's research into sarcopenia, an age-related disease that can occur as early as the age of 50. The work of the UNamur researcher and member of the Narilis Institute has been rewarded once again, as she has just been awarded the title of "Namuroise of the Year", for the Sciences category!
See content
Skin infections: UNamur partners in Win²WAL research project
The TineaDiag project is a research project run by UNamur and ULiège with funding from the SPW Research Win²WAL program. It tackles dermatophytoses, skin infections responsible for ringworm, which can affect both humans and animals. The aim? To identify, in dermatophytes, precise cellular markers in order to detect them with sensitivity and certainty, and thus identify infections caused by antifungal-resistant strains.
See content
Louise Gérard
Safer oral contraceptives thanks to natural estrogens
A major breakthrough for the health of women on oral contraceptives has been achieved by researchers in Namur. Every year in Europe, more than 22,000 cases of venous thrombosis or embolism occur among contraceptive pill users. A team of researchers from the University of Namur, in collaboration with QUALIblood (spin-off), has conducted an important study, the results of which could transform prescribing recommendations..
See content
Facilitating the authorization of pediatric and orphan drugs
Bringing a new drug to market, particularly when it is intended to treat a pediatric or orphan disease, is a journey fraught with pitfalls. The ERAMET project, coordinated by Professor Flora Musuamba Tshinanu, aims to overhaul the assessment procedures, so that regulatory agencies can take innovative technologies into account and thus make more informed choices.
See content
Medical Journal Club in primary care
Target audienceGeneral practitioners (in practice or in training)PharmacistsMedical and pharmacy studentsObjectivesShare and discuss scientific articles relevant to frontline practice in a friendly and caring atmosphereStrengthen skills in critical reading and evidence-based medicineCreate a lasting link between the field and the academic worldFederate an active and committed medico-pharmaceutical community.pharmaceutical communityWhy participate?Because science moves fast, and we all benefit from taking the time to read, understand, and question the literature together. Because quality care starts with shared reflection. And because it's the ideal opportunity to strengthen bridges between disciplines.Location and frequency of meetingsUNamur - Quai22 - 2 times a yearFirst meeting: 5/06/2025 (free with registration)INAMI accreditation required.
I want to register
See content
Thomas Balligand: from Medicine to Fundamental Research at UNamur
Thomas Balligand, now a lecturer at UNamur, combines his passion for basic research with teaching in histology and cytology. After a diverse background in internal medicine and research, notably at Harvard, he is dedicated to training the next generation of scientists while pursuing his work on nanobodies and their potential in immunotherapy. His desire to awaken scientific curiosity in his students illuminates his new role at the university..
See content